Back to homepage

Tag "heart failure"

The impact of antidepressants on depressive symptom severity, quality of life, morbidity, and mortality in heart failure: a systematic review

Authors: Rebecca Hedrick MD, Samuel Korouri BA, Emile Tadros BS, Tarneem Darwish MD, Veronica Cortez RN, OD, Desiree Triay RN, Mia Pasini RN, MSN, Linda Olanisa LCSW, Nathalie Herrera MD, Sophia Hanna BA, MA, Asher Kimchi MD, Michele Hamilton MD, Itai Danovitch MD, MBA, Waguih William IsHak MD, FAPA

This article reviews the literature on the impact of antidepressants on depressive symptom severity, quality of life, morbidity, and mortality in patients with heart failure.

More

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition

Authors: Muhammad Saad MD, Umut Gomceli MD, Pranav Ravi MD, Andrisael G Lacoste MD, Neil Shah MD, Timothy J Vittorio MD

In the recent era, SGLT-2 inhibitors have shown success in decreasing cardiovascular mortality in the type 2 diabetes mellitus population. This article will help the reviewer to comprehend the pathophysiology of heart failure and the potential role of SGLT-2 inhibitors in the management algorithm of heart failure and its associated risk factors in type 2 diabetes mellitus.

More

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil

Authors: Edgardo Kaplinsky MD, Gordon Mallarkey PhD

This article examines omecamtiv mecarbil, which is a first-in-class cardiac myosin activator used in the treatment of heart failure.

More

Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond

Authors: Elif A Oral

This paper summarizes the results from the ground-breaking EMPA-REG OUTCOME study and discusses their significance and clinical implications.

More